Protein kinase C-β II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab

被引：13

作者：

Chaiwatanatorn, Kritika ^{[1
,2
]}

Stamaratis, Georgia ^{[3
]}

Opeskin, Ken ^{[3
]}

Firkin, Frank ^{[1
,2
]}

Nandurkar, Harshal ^{[1
,2
]}

机构：

[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia

[2] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia

[3] St Vincents Hosp, Dept Anat Pathol, Melbourne, Vic, Australia

来源：

LEUKEMIA & LYMPHOMA | 2009年 / 50卷 / 10期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Protein kinase C-beta; diffuse large B-cell lymphoma; prognostic indicator; chemotherapy; rituximab; PKC-BETA; R-CHOP; PROGNOSTIC IMPACT; ELDERLY-PATIENTS; SURVIVAL; CLASSIFICATION; ACTIVATION; DEFICIENT;

D O I：

10.1080/10428190903165233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Protein kinase C-beta II (PKC-beta II) expression has been reported to indicate inferior prognosis in diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-based chemotherapy. This study compared prognostic significance of immunohistochemically determined PKC-beta II expression in de novo DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy with and without rituximab. Outcomes were assessed in 80 consecutive patients, 48 treated with CHOP, and 32 with rituximab plus CHOP (R-CHOP). PKC-beta II expression correlated with inferior overall survival (OS) and progression-free survival (PFS) in CHOP-treated patients with low-risk International Prognostic Index (IPI) disease (0-2 adverse factors), but not in the overall patient group unstratified by IPI. PKC-beta II expression correlated with inferior OS and PFS in R-CHOP-treated patients unstratified by IPI status. Immunohistochemically demonstrated PKC-beta II expression thus identified patient subgroups where alternative treatment strategies may confer superior outcome. We now report that PKC-beta II expression has prognostic significance not only for CHOP therapy in low-risk IPI disease, but also for all patients receiving CHOP plus rituximab.

引用

页码：1666 / 1675

页数：10

共 28 条

[21] Building an outcome predictor model for diffuse large B-cell lymphoma [J].

Sáez, AI ;

Sáez, AJ ;

Artiga, MJ ;

Pérez-Rosado, A ;

Camacho, FI ;

Díez, A ;

García, JF ;

Fraga, M ;

Bosch, R ;

Rodríguez-Pinilla, SM ;

Mollejo, M ;

Romero, C ;

Sánchez-Verde, L ;

Pollán, M ;

Piris, MA .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (02) :613-622

[22] Protein kinase C β controls nuclear factor κB activation in B cells through selective regulation of the IκB kinase α [J].

Saijo, K ;

Mecklenbräuker, I ;

Santana, A ;

Leitger, M ;

Schmedt, C ;

Tarakhovsky, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (12) :1647-1652

[23] PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma [J].

Schaffel, Rony ;

Morais, Jose C. ;

Biasoli, Irene ;

Lima, Joana ;

Scheliga, Adriana ;

Romano, Sergio ;

Milito, Cristiane ;

Spector, Nelson .

MODERN PATHOLOGY, 2007, 20 (03) :326-330

[24] The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J].

Sehn, Laurie H. ;

Berry, Brian ;

Chhanabhai, Mukesh ;

Fitzgerald, Catherine ;

Gill, Karamjit ;

Hoskins, Paul ;

Klasa, Richard ;

Savage, Kerry J. ;

Shenkier, Tamara ;

Sutherland, Judy ;

Gascoyne, Randy D. ;

Connors, Joseph M. .

BLOOD, 2007, 109 (05) :1857-1861

[25] Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning [J].

Shipp, MA ;

Ross, KN ;

Tamayo, P ;

Weng, AP ;

Kutok, JL ;

Aguiar, RCT ;

Gaasenbeek, M ;

Angelo, M ;

Reich, M ;

Pinkus, GS ;

Ray, TS ;

Koval, MA ;

Last, KW ;

Norton, A ;

Lister, TA ;

Mesirov, J ;

Neuberg, DS ;

Lander, ES ;

Aster, JC ;

Golub, TR .

NATURE MEDICINE, 2002, 8 (01) :68-74

[26] A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].

SHIPP, MA ;

HARRINGTON, DP ;

ANDERSON, JR ;

ARMITAGE, JO ;

BONADONNA, G ;

BRITTINGER, G ;

CABANILLAS, F ;

CANELLOS, GP ;

COIFFIER, B ;

CONNORS, JM ;

COWAN, RA ;

CROWTHER, D ;

DAHLBERG, S ;

ENGELHARD, M ;

FISHER, RI ;

GISSELBRECHT, C ;

HORNING, SJ ;

LEPAGE, E ;

LISTER, TA ;

MEERWALDT, JH ;

MONTSERRAT, E ;

NISSEN, NI ;

OKEN, MM ;

PETERSON, BA ;

TONDINI, C ;

VELASQUEZ, WA ;

YEAP, BY .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994

[27] PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling [J].

Su, TT ;

Guo, BC ;

Kawakami, Y ;

Sommer, K ;

Chae, K ;

Humphries, LA ;

Kato, RM ;

Kang, S ;

Patrone, L ;

Wall, R ;

Teitell, M ;

Leitges, M ;

Kawakami, T ;

Rawlings, DJ .

NATURE IMMUNOLOGY, 2002, 3 (08) :780-786

[28] Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study [J].

Winter, Jane N. ;

Weller, Edie A. ;

Horning, Sandra J. ;

Krajewska, Maryla ;

Variakojis, Daina ;

Habermann, Thomas M. ;

Fisher, Richard I. ;

Kurtin, Paul J. ;

Macon, William R. ;

Chhanabhai, Mukesh ;

Felgar, Raymond E. ;

Hsi, Eric D. ;

Medeiros, L. Jeffrey ;

Weick, James K. ;

Reed, John C. ;

Gascoyne, Randy D. .

BLOOD, 2006, 107 (11) :4207-4213

← 1 2 3 →